Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Business News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Amedica buys US Spine: Orthopedic device maker expands its spinal implant offerings through the acquisition of privately held US Spine for undisclosed terms on Sept. 21. Boca Raton-based US Spine offers "certain facet technologies that address open, [minimally invasive surgery], allograft, and deformity correction procedures," which complement Amedica offerings including Valeo silicon nitride ceramic spinal implants, Amedica says. The Salt Lake City firm now can offer a full line of spinal implants and instruments, according to the company. The deal also doubles Amedica's distribution network and sales and marketing management while enhancing its international presence, the company said. Earlier this month, Amedica raised $30 million, including $15 million in private equity and a $15 million debt facility, to fuel sales, marketing and potential acquisitions (1"The Gray Sheet" Sept. 13, 2010)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel